Bioinformatics is a field of science that integrates computer technology to analyze biological data, particularly DNA and protein sequences, to advance therapies and boost healthcare research. In this article, we take a look at five companies at the top of their bioinformatics game in 2024.SynthaceBritish-American life science company Synthace’s DNA Assembly platform allows people to import assembly design files at the start of the workflow, after which, it helps create the plasmids – circular DNA molecules found in microbes – that are required for projects.Once customers specify what kind of plasmid they want designed, Synthace’s platform calculates the liquid movements, concentrations, and dilutions needed throughout the entire process. The company helps estimate reagent volumes as well as automation instructions for customers to be able to run experiments without having to use spreadsheets or any kind of programming. With a focus on molecular biology, the bioinformatics company aids scientists in planning and automating processes like DNA assembly for their research and development (RD) projects.Synthace has previously worked with tech giants like Microsoft to design manufacturing processes for lentiviral vectors to be able to program cells to discover new medicines. It has also collaborated with global biopharma Ipsen to develop medicines to treat rare diseases and pain relief.  The company has also been known to use OpenAI’s ChatGPT to design complex experiments.Last year, Synthace was among 50 companies like Google, mental healthcare company Headspace, and food company Beyond Meat, to win the international Impact Fifty award recognizing the most impactful companies to work for.Verge GenomicsImmersed in the drug discovery space, Verge Genomics leverages artificial intelligence (AI) to discover and develop drugs. Its CONVERGE discovery platform is a closed-loop machine learning system that combines genomics and computational tools to scout for drug targets and predict how well investigational medicines could perform in the clinic.This way, it looks to develop drugs at a faster rate. In its pipeline, Verge has an amyotrophic lateral sclerosis (ALS) drug undergoing proof-of-concept studies. ALS is a fatal motor neuron disease that affects the nerve cells in the spinal cord and brain

VRG50635, a small molecule PIKfyve inhibitor, is one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platformVerge’s proof-of-concept study uses first-of-its-kind, cutting-edge design and technology to deliver more precise and comprehensive insights into how VRG50635 may benefit individuals with ALS“I applaud Verge for creating a bold proof-of-concept design that incorporates cutting-edge technology and scientific innovation in their efforts to create groundbreaking therapies for ALS.” - Dr. Angela Genge, Director, ALS Centre of Excellence for Research and Patient Care, Montreal Neurological Institute-Hospital SOUTH SAN FRANCISCO, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data, today announced the initiation of its Phase 1b proof-of-concept study of VRG50635 for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS). The study will assess the safety and tolerability of escalating doses of VRG50635, a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, the company’s all-in-human, AI-powered platform. VRG50635 is one of the first drugs to enter the clinic that was entirely discovered and developed from an AI-enabled platform.In traditional ALS clinical trials, a patient's progress is measured in a clinical setting using poorly responsive physician rating scales, which typically provide sparse data to establish proof of concept early in clinical development. In contrast, Verge's study harnesses the power of digital devices to collect thousands of objective, quantitative, relevant measurements directly from the patient, including mobility, breathing, and sleeping all from the comfort of their home

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) - Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data, today announced the initiation of its Phase 1b proof-of-concept study of VRG50635 for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS).